In a report released yesterday, Tom Jones from Berenberg Bank maintained a Buy rating on Grifols (0RDU – Research Report), with a price target ...

Berenberg analyst Tom Jones lowered the firm’s price target on Grifols (GRFS) to EUR 15.25 from EUR 15.40 and keeps a Buy rating on the ...

Spanish plasma-derived medicines specialist Grifols revealed it is collaborating with Dutch biotechnology start-up, FcR ...

Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, has announced a collaboration with ...

‘Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms appear, leading to new diagnostic tools and ...

The selective Spanish stock market, the IBEX 35, continues to extend gains and is already up 0.80% at noon, standing above 12 ...

While still robust, CSL half-year results last Weds revealed impact of an “alarming” fall off in 'flu vax rates, especially ...

(Bloomberg) -- Drugmaker Grifols SA and US short seller Gotham City Research are counting on two different reports from a Spanish regulator to bolster their cases as they prepare to face off in court.